JP2024520427A5 - - Google Patents

Info

Publication number
JP2024520427A5
JP2024520427A5 JP2023572797A JP2023572797A JP2024520427A5 JP 2024520427 A5 JP2024520427 A5 JP 2024520427A5 JP 2023572797 A JP2023572797 A JP 2023572797A JP 2023572797 A JP2023572797 A JP 2023572797A JP 2024520427 A5 JP2024520427 A5 JP 2024520427A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030814 external-priority patent/WO2022251283A1/en
Publication of JP2024520427A publication Critical patent/JP2024520427A/ja
Publication of JP2024520427A5 publication Critical patent/JP2024520427A5/ja
Pending legal-status Critical Current

Links

JP2023572797A 2021-05-25 2022-05-25 Ras変異を標的とするt細胞受容体およびその使用 Pending JP2024520427A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
US63/192,783 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520427A JP2024520427A (ja) 2024-05-24
JP2024520427A5 true JP2024520427A5 (cg-RX-API-DMAC7.html) 2025-06-03

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572797A Pending JP2024520427A (ja) 2021-05-25 2022-05-25 Ras変異を標的とするt細胞受容体およびその使用

Country Status (11)

Country Link
US (1) US20240091361A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347639A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520427A (cg-RX-API-DMAC7.html)
KR (1) KR20240013750A (cg-RX-API-DMAC7.html)
CN (1) CN117545766A (cg-RX-API-DMAC7.html)
AU (1) AU2022283277A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219923A1 (cg-RX-API-DMAC7.html)
IL (1) IL308755A (cg-RX-API-DMAC7.html)
MX (1) MX2023014073A (cg-RX-API-DMAC7.html)
WO (1) WO2022251283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573114A4 (en) * 2022-08-19 2026-07-29 Memorial Sloan Kettering Cancer Center T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
US20260232734A1 (en) * 2023-02-27 2026-08-13 Adaptive Biotechnologies Corporation Therapeutic T-Cell Receptors Targeting KRAS G12D
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术(广东)有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
WO2025054164A1 (en) * 2023-09-05 2025-03-13 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
AU2024408100A1 (en) * 2023-12-22 2026-08-06 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
US20200129555A1 (en) * 2018-10-24 2020-04-30 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2613715B (en) * 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof

Similar Documents

Publication Publication Date Title
JP2022527635A5 (cg-RX-API-DMAC7.html)
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP7803939B2 (ja) Kras変異に特異的t細胞受容体のスクリーニング及び抗腫瘍用途
US20240024359A1 (en) BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20
AU2017371260B2 (en) T cell receptors with improved pairing
JP7340127B2 (ja) がんに対する免疫療法で使用するための形質移入t細胞およびt細胞受容体
ES2968802T3 (es) Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
JP2021533777A5 (cg-RX-API-DMAC7.html)
JP2022050400A5 (cg-RX-API-DMAC7.html)
JP2021520831A5 (cg-RX-API-DMAC7.html)
JP2017523784A5 (cg-RX-API-DMAC7.html)
JP2017536825A (ja) 抗突然変異kras t細胞受容体
JP2025063321A5 (cg-RX-API-DMAC7.html)
JP2022527267A5 (cg-RX-API-DMAC7.html)
JP2022528030A5 (cg-RX-API-DMAC7.html)
CN112930394A (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
US12421290B2 (en) CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies
CA3115022A1 (en) Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
JP2022537553A5 (cg-RX-API-DMAC7.html)
JP2022548112A5 (cg-RX-API-DMAC7.html)
JP2022502078A5 (cg-RX-API-DMAC7.html)
JP2023540123A5 (cg-RX-API-DMAC7.html)
Parsons et al. A novel CEA vaccine stimulates T cell proliferation, γIFN secretion and CEA specific CTL responses
JP2023526416A5 (cg-RX-API-DMAC7.html)
JP2023052688A (ja) 対合が改善されたt細胞受容体t細胞